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A B S T R A C T
Increasing evidence has indicated that the non-coding RNA molecules play central roles in almost all biological processes 
and many pathological conditions including carcinogenesis. This review focuses on the pathological tumorigenic role of the 
first discovered long non-coding RNA gene called H19 and its pivotal contribution to the cancer axis of evil. H19 RNA utilizes 
a variety of mechanisms to perform its pathological function. Some key unanswered questions are presented by the end. 
Understanding the H19 RNA mechanisms of action will shed light into the class of long non-coding RNA which contains 
contains thousands of members mostly with unknown functionn and will help in delineating the pathological role played by 
at least some of them
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After realizing that our DNA is a 
transcription machine, with a little protein 
coding potential, the past decade has witnessed 
an explosion in scientific researches reporting 
the identifications, characterizations and 
exploration of the modes of action of the non-
coding RNA (ncRNA) genes. Currently, the ncRNA 
research field is one of the most popular fields 
in biological and medical sciences. An ncRNA is 
an RNA molecule that is not translated into a 
protein product and is classified according to its 
size into a long (more than 200 nucleotide) and a 
short (less than 200 nucleotide) ncRNA. The vast 
knowledge accumulated during the past decade 
was su!cient for the scientific community to 
announce the entry into the fascinating ncRNA 
era which was and still dominated by the 
microRNAs (miRNA) researches. The miRNAs 
are small ncRNA mediating regulation of gene 
expression and their discovery has changed 
vastly the way we used to think about gene 
regulation.
The functions and mechanisms of action 
of the long non-coding RNAs (lncRNAs) are the 
least understood aspect of the ncRNA biology. 
Many thousands of lncRNAs are produced from 
our genome, yet relatively very few have well 
documented roles. This review will handle a 
gene called H19, which transcribes to an lncRNA.. 
Being the first imprinted lncRNA discovered, our 
knowledge on H19 is relatively high compared to 
the others. This is especially reflected by the steep 
increase in the scientific reports handling the H19 
lncRNA functions and its modes of action that 
occurred in the past few years after decades of 
relative dormancy. H19 is expressed in the placenta 
and in the embryonic stage but shut down in 
most tissues after birth and re-expressed again in 
almost all cancer types.
The roles  of H19 in cancer are diverse and 
Correspondance: Department of Life Sciences, College of Science    
    & Technology, Jerusalem, Palestine. 
    E-mail: imatook@sta".alquds.edu
c  copy rights 2021: All materials in this article is protected, 
     permission requests should be addressed to Al-Quds University. 
    www.alquds.edu
Al-Quds Journal for 
Academic Research
10
touches almost every aspect of the tumorigenesic 
process. This review  focuses into the well-
established  mechanistic roles of the H19 lncRNA 
in the epithelial to mesenchymal transition 
(EMT), cancer stem cells,  and drug resistance, 
collectively called “cancer axis of evil” (Singh 
and  Settleman, 2010), as they are responsible 
for the tumor metastasis and the failure of the 
chemotherapeutic drugs. This dictates indeed 
the cancer deadly signature. EMT is a reversible 
trans-di"erentiation process through which the 
non-motile epithelial cells are converted to motile 
mesenchymal cells, a step that is essential for 
tumor invasion and subsequent metastasis. Cancer 
stem cells are rare cancer cell population within 
the tumor that have stem-cell like properties and 
is greatly believed among the scientific community 
that these cells are responsible for fueling tumor 
growth, tumor heterogeneity, drug resistance and 
invasion. Some examples into other physiological 
and pathological roles for H19 are presented when 
needed for clarifications. It is astonishing how H19 
can employs diverse mechanisms to perform its 
specific functions. An illustration of three (among 
others) well documented modes of action for H19 
lncRNA is presented.
H19 lncRNA functions as a scavenger through 
sponging miRNAs.
One of the well-established modes of 
action through which the H19 lncRNA performs 
its function is by acting as a competing 
endogenous RNA (ceRNA) for the purpose of 
“sponging” appropriate candidate miRNAs. By 
this H19 relieves the sponged miRNA inhibitory 
e"ect on its downstream targets and thus acts 
as a scavenger. 
One of the earliest reports showed a conserved 
role for H19 in modulation the major let-7 
family availability by acting as a molecular 
sponge. Consequently, H19 a"ects expression 
of endogenous Let-7 targets including Dicer and 
Hmga2 (Kallen et al., 2013), a multifunctional 
proteins with broad activities. A double negative 
feedback loop between H19, let-7 miRNA and 
the pluripotency factor LIN28 has a critical role 
in the maintenance of breast cancer stem cell 
properties (Peng et al., 2018). Additional report 
indicates that oestrogen induction symmetric 
division in breast cancer stem-like cells is 
regulated by H19 through antagonizing Let!7c( 
Wang et al., 2019). We were the first to document 
that H19 is induced by hypoxic stress through 
the Hypoxia-inducible factor 1a (HIF1-a) pathway 
(Matouk et al., 2010). An interesting recent report 
indicated that H19 is responsible for glycolysis 
and breast cancer stem cells (BCSC) maintenance. 
Mechanistically H19 acting as ceRNA sequesters 
miRNA let-7 miRNA to release HIF1-a, leading 
to an increase in pyruvate dehydrogenase 
kinase 1 (PDK1) expression. PDK1 enhances BCSC 
properties and is correlated with poor overall 
survival (Peng et al., 2018).
We have provided several evidences for 
H19 central role in epithelial to mesenchymal 
transition (EMT) process (Matouk et al., 2014) 
and suggested that H19 can also act as an 
orchestrator for the EMT-MET processes ( Matouk 
et al., 2016). Multiple reports have indicated 
that this can be performed at least in part 
through the sponging activity of H19 lncRNA. 
For instance, by derepressing let-7’s suppression 
on its target HMGA2, H19 promotes EMT and 
metastasis in pancreatic cancer model (Ma et 
al., 2013). Additionally, in colorectal cancer it 
was demonstrated that H19 sponges miR-138 
and miR-200a that led to the de-repression of 
their endogenous targets Vimentin, ZEB1, and 
ZEB2, all are well established marker genes for 
mesenchymal cells (Liang et al., 2015) Furthermore 
it was shown that through di"erentially 
sponging miR-200b/c and let-7b, H19 mediates 
breast cancer cell plasticity during EMT and MET 
processes (Zhou et al., 2017). In glioma, H19 could 
compete with SOX4 via sponging miR-130a-3p 
and thus regulating EMT (Hu et al., 2018). H19 
sponges miR-29b-3p and relieve the suppression 
for DNMT3B, which led to EMT and metastasis of 
bladder cancer (Lv et al., 2017).
By acting as ceRNA, several reports have 
indicated  that H19 confer cancer chemoresistance 
in various models. H19 sponges miR-194–5p thus 
confers 5-Fu resistance in colorectal cancer by 
promoting SIRT1-mediated autophagy (Wang 
et al., 2018). Additionally, H19 acts as a miRNA-
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106b-5p sponge and thus impairs the function 
of miRNA-106b-5p on its target gene, TDRG1. By 
this, H19 facilitate cell survival in cisplatin-based 
chemotherapeutic conditions in seminoma (Wei 
et al., 2018). Bortezomib resistance in multiple 
myeloma is also enhanced by H19 by acting as a 
miRNA sponge to inhibit the expression of miR-
29b-3p, enhance MCL-1 transcriptional translation 
and inhibit apoptosis (Pan et al., 2019). A recent 
study indicates that H19 confers resistance 
to gefitinib via miR-148b/dimethylarginine 
dimethylaminohydrolase-1 (DDAH1) axis in 
lung adenocarcinoma. Mechanistically, RNA 
H19 positively regulated DDAH1 expression via 
sponging miR-148b-3p (Huang et al., 2020).
 
H19 is a precursor for miR-675-5p and miR-675-3p
Discovered in 2007 miR-675 processed 
from the first and longest H19 exon (Cai and 
Cullen. 2007). MiR-675 was reported to target the 
“retinoplastoma gatekeeper of DNA replication” 
(Tsang et al., 2010) and the “p53 Guardian of the 
genome” ( Zheng et al., 2019) both were among the 
best characterized  and well established tumor 
suppressor genes. The inhibitory e"ect of miR-
675 on p53 could have a myriad consequences 
given hundreds of targets that p53 has the 
ability to modulate. We were the first to report 
that p53 suppress H19 induction upon hypoxic 
stress (Matouk et al,. 2010) and the upregulation 
of miR-675 in response to hypoxia ( Matouk et 
al,. 2014). So the possibility of feedback loops 
between H19-miR-675-P53 by which miR-675b 
elevate the inhibitory e"ect of p53 on H19 upon 
hypoxic stress could be the case. Among other 
well-known tumor suppressor genes targeted 
by miR-675 is RUNX1 (Zhuang et al., 2014), and 
PTEN ( Lv et al., 2018) though the latter was not 
tested in the context of tumorigenicity. Thus 
it is not astonishing that at least part of the 
pathological role of H19 is mediated by miR-
675. MiR-675 targets a myriad of transcripts in 
a cellular-context-dependent manner involved 
in proliferation, apoptosis, EMT, invasion, 
migration, drug resistance, angiogenesis, and 
cancer stemness. Although some conflicting 
data have been reported in di"erent research 
models, the prevailing view is that miR-675 is 
functioning as an onco-miR in most models. 
Physiologically, miR-675 is expressed exclusively 
in the placenta from the gestational time point 
when placental growth normally ceases. When 
lacking H19, the placentas continue to grow 
suggesting that the physiological role of H19 is 
to limit placental growth through its microRNA 
tool. Results indicate that miR-675 slows cell 
proliferation through at least in part targeting 
insulin like growth factor receptor 1 (Igf1r), the 
key receptor through which Igf2 signal to promote 
growth during fetal development (Keniry et al., 
2012).
Additional physiological roles for miR-675 
have been described in promoting skeletal muscle 
di"erentiation and regeneration ( Dey et al., 2014) 
and the regulation of  intestinal epithelial barrier 
(Zou et al., 2016).  
H19 lncRNA epigenetically modulate gene 
expression
Since H19’s discovery in 1984, its locus 
has been used as a dogma to study epigenetic 
regulation of the imprinted genes where H19 
also act in cis modulating and fine tuning the 
imprinting of other genes within the imprinted 
cluster where it resides. In this section the 
emerging role of H19 in epigenetic regulation 
of gene expression in Trans is handled which 
was uncovered in the past few years. H19 
lncRNA interacts with transcription-repressors 
functioning epigenetically and guide them to 
specific loci. For example H19 binds the methyl-
CpG–binding domain protein 1 (MBD1) and 
recruits it to some of its targets, by doing so H19 
enables the maintaining of repressive H3K9me3 
histone marks in their loci (Monnier et al., 2013).
Enhancer of zeste homolog 2 (EZH2) is a critical 
component of Polycomb-Repressive Complex 2 
(PRC2). EZH2 is responsible for generating histone 
H3 lysine 27 trimethylation, a modification that 
always correlates with transcriptionally repressed 
chromatin. Several reports uncover a “partnership” 
between H19 and EZH2. Even more dramatic are 
reports covering that H19 regulate EZH2 expression 
itself. EZH2 is regulated by H19, through sponging 
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of miR-630 (Li et al., 2016). Additionally, and 
through sponging miR-130, it was reported that 
H19 regulate EZH2 expression (Hong et al. 2018). 
The functional outputs of H19-EZH2 association 
have been reported in a number of studies and 
using di"erent models. Upregulated H19 enhances 
bladder cancer metastasis by associating with EZH2 
and inhibiting E-cadherin expression. The authors 
showed that this association resulted in directly 
suppressing Ecadherin transcription and indirectly 
activating the Wnt signaling pathway (Luo et al., 
2013). In tongue squamous cell carcinoma, it was 
shown that H19 promotes carcinoma progression 
through β-catenin / GSK3β/EMT signaling via 
association with EZH2 ( Zhang et al., 2017). 
Additionally, in esophageal cancer H19 facilitates 
EMT and metastasis through let-7c/STAT3/EZH2/β-
catenin axis (Chen et al., 2019). Furthermore, in 
glioblastoma cells H19 regulate NKD1 transcription 
via EZH2-induced H3K27 trimethylation of its 
promoter resulting in the repression of Nkd1-a 
negative regulator of Wnt pathway (Fazi et al/. 2018). 
In diabetic cardiomyopathy model, H19 inhibits 
autophagy by epigenetically silencing of DIRAS3. 
H19 knockdown could reduce EZH2 occupancy and 
H3K27me3 binding in the promoter of DIRAS3 (Zhuo 
et al., 2017). Perhaps the most dramatic finding 
of the large scale (genome wide) epigenetic 
e"ect of H19 was reported by Zhou et al. (Zhou 
et al., 2015). In this report, it was shown that H19 
binds to and inhibits S-adenosylhomocysteine 
hydrolase (SAHH), the only mammalian enzyme 
capable of hydrolysing S-adenosylhomocysteine 
(SAH). This enzyme is a potent feedback inhibitor 
of S-adenosylmethionine (SAM)-dependent 
methyltransferases that methylate nucleic acids, 
proteins and lipids. SAHH modulation by H19 thus 
exerts global e"ects by causing methylation 
changes at numerous gene loci genome-wide. 
This represents the first case in which H19 acts in 
trans to alter the epigenetic landscape genome-
wide. 
The influence of H19 lncRNA extends beyond the 
cells transcribing it
With the discovery that RNA could be 
secreted outside the cells through exosomal 
vesicles, and cause phenotypic change in the cells 
receiving them, major changes about the local 
(cells transcribing it) phenotypic e"ect of these 
transcripts have been challenged with a very 
long believe that this function is only attributed 
to proteins. Cells communicated through RNA 
exosomes is relatively novel and could happen 
between normal cells, between cancer cells, and 
between normal and cancer cells. H19 lncRNA 
has functions far outside the cells transcribing 
it.Multiple reports indicate that exosomal H19 
can induce drug resistant. For example exosomal 
H19 facilitated erlotinib and gefitinib resistance 
in non-small cell lung cancer (NSCLC) (Pan et al., 
2020, Lei et al., 2020), H19 is delivered by exosomes 
to sensitive cells, leading to the dissemination of 
doxorubicin resistance in breast cancer (Wang et 
al.,2020). Carcinoma-associated fibroblasts promote 
the stemness and chemoresistance of colorectal 
carcinoma by transferring exosomal H19 ( Ren et 
al., 2018). Additional reports have indicated that 
exosomal H19 induce other phenotypes related to 
tumorigenesis including stemness, angiogenesis, 
cell invasion and migration and proliferation.
Interestingly many of those phenotypes are induced 
in recipient cells with similar H19 scenarios of 
action to those described in the previous sections. 
In summation, it is increasingly clear that the 
H19 lncRNA is a major player and a corner stone 
of many facets of the tumorigenic processes. It’s 
an ideal target for therapeutic intervention. It 
uses diverse tools embedded in its primary RNA 
sequences to act as a sponger or a producer of 
microRNA (Figure 1). 
Globally, H19 modify gene expression 
through epigenetic regulation genome wide. 
Despite this impressive progress made in the 
past decade, still we have many points need 
to be addressed for better understanding.We 
have highlighted the importance of H19 lncRNA 
during many stages of tumorigenesis.  We 
are aware that the vast scenarios presented 
above are collected from di"erent models and 
situations. So what dictates the mode of action? 
For instance, E-cadherin is suppressed by H19 
by at least three modes of action as a sponger 
and a producer of microRNA, and also through 
epigenetic regulation. 
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Are these scenarios happening concurrently 
in the same cancer cells to assure E-cadherin 
suppression or each scenario is happening in 
a tissue-specific manner? What triggers the 
release of H19 through the exosomes? Do H19 
and miR-675 have di"erent regulatory sequences, 
taking into consideration that they are both 
upregulated in many cancer types and it seems 
that miR-675 is not produced an the expense of 
H19. Why are still some reports arguing for a 
tumor suppressor function of H19 and its miR-
675- Is H19 gene locus playing a dual role? If yes 
what triggers each role. Another question that 
needs to be addressed is whether H19 lncRNA is 
also acting as an antisense transcript given that 
its locus also transcribed in antisense direction. 
Certainly, understanding the di"erent 
mode of actions performed by H19 lncRNA will 
foster our thoughts towards delineating the 
possible roles and the mechanism of action of 
so many lncRNA with unknown function. It is not 
odd to speculate that the mechanistic mode of 
action of H19 is shared by other lncRNAs.
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